Bojangles’, Inc. Reports Financial Results for its Fourth Fiscal Quarter and Fiscal Year 2016
Mar 07, 2017 21:06 pm UTC| Business
CHARLOTTE, N.C., March 07, 2017 -- Bojangles’, Inc. (Bojangles’) (NASDAQ:BOJA) today announced financial results for the 13-week fourth fiscal quarter and 52-week fiscal year ended December 25, 2016. Bojangles’ also...
RLHC Reports Fourth Quarter and Full Year 2016 Preliminary Unaudited Results
Mar 07, 2017 21:06 pm UTC| Business
SPOKANE, Wash., March 07, 2017 -- Red Lion Hotels Corporation (“RLHC” or "the company") (NYSE:RLH), a growing hospitality company that operates and franchises upscale, midscale and economy hotels, today reported...
RLHC Reports Fourth Quarter and Full Year 2016 Preliminary Unaudited Results
Mar 07, 2017 21:06 pm UTC| Business
SPOKANE, Wash., March 07, 2017 -- Red Lion Hotels Corporation (“RLHC” or "the company") (NYSE:RLH), a growing hospitality company that operates and franchises upscale, midscale and economy hotels, today reported...
Mar 07, 2017 21:05 pm UTC| Business
IND for RGX-314 Phase I trial for wet AMD is active and dosing initiated for RGX-501 Phase I/II trial for HoFHInterim trial updates for RGX-314 and RGX-501 expected by year-end 2017 $159 million in cash, cash equivalents...
Urban Outfitters Reports Record Sales
Mar 07, 2017 21:05 pm UTC| Business
PHILADELPHIA, March 07, 2017 -- Urban Outfitters, Inc. (NASDAQ:URBN), a portfolio of global consumer brands comprised of Anthropologie, Bhldn, Free People, Terrain and Urban Outfitters brands and our Food and Beverage...
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
Mar 07, 2017 21:05 pm UTC| Business
LA JOLLA, Calif., March 07, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report...
Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
Mar 07, 2017 21:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., March 07, 2017 -- Portola PharmaceuticalsInc.® (Nasdaq:PTLA) today announced thatnew data from the pivotal Phase 3 APEX Study of the Company’s investigational drug betrixaban will be...